Therefore, further investigation of therapeutic strategies by co-targeting reciprocal interactions of AR and IGF1 pathways between epithelial tumor cells and surrounding tumor niches may improve clinical outcomes for advanced prostate cancer. The gene discussed is IGF1; the disease is prostate carcinoma.